Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,583,308
  • Shares Outstanding, K 84,987
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,360 K
  • 60-Month Beta 0.91
  • Price/Sales 416.37
  • Price/Cash Flow N/A
  • Price/Book 3.54
Trade SNDX with:

Options Overview Details

View History
  • Implied Volatility 54.21% ( +10.84%)
  • Historical Volatility 35.58%
  • IV Percentile 21%
  • IV Rank 14.17%
  • IV High 230.38% on 09/29/23
  • IV Low 25.12% on 06/04/24
  • Put/Call Vol Ratio 1.81
  • Today's Volume 208
  • Volume Avg (30-Day) 852
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 25,039
  • Open Int (30-Day) 13,631

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.13
  • Number of Estimates 7
  • High Estimate -1.05
  • Low Estimate -1.26
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -54.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.34 +7.44%
on 09/18/24
21.56 -13.59%
on 09/03/24
-1.87 (-9.12%)
since 08/19/24
3-Month
17.34 +7.44%
on 09/18/24
25.07 -25.69%
on 07/26/24
-0.43 (-2.26%)
since 06/18/24
52-Week
11.22 +66.12%
on 10/23/23
25.34 -26.48%
on 02/28/24
+1.56 (+9.14%)
since 09/19/23

Most Recent Stories

More News
Syndax: Q2 Earnings Snapshot

Syndax: Q2 Earnings Snapshot

SNDX : 18.63 (-0.43%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

SNDX : 18.63 (-0.43%)
ATNM : 1.9097 (+1.58%)
KURA : 20.86 (-1.04%)
BMEA : 8.71 (+0.05%)
JNJ : 164.12 (-0.42%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

SNDX : 18.63 (-0.43%)
ATNM : 1.9097 (+1.58%)
KURA : 20.86 (-1.04%)
BMEA : 8.71 (+0.05%)
JNJ : 164.12 (-0.42%)
Syndax: Q1 Earnings Snapshot

Syndax: Q1 Earnings Snapshot

SNDX : 18.63 (-0.43%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 18.63 (-0.43%)
Syndax: Q3 Earnings Snapshot

Syndax: Q3 Earnings Snapshot

SNDX : 18.63 (-0.43%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 18.63 (-0.43%)
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14%...

SNDX : 18.63 (-0.43%)
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 18.63 (-0.43%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 18.63 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 20.35
2nd Resistance Point 19.70
1st Resistance Point 19.16
Last Price 18.63
1st Support Level 17.97
2nd Support Level 17.32
3rd Support Level 16.78

See More

52-Week High 25.34
Fibonacci 61.8% 19.94
Last Price 18.63
Fibonacci 50% 18.28
Fibonacci 38.2% 16.61
52-Week Low 11.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar